Affinia receives FDA approval for Phase I/II trial for dilated cardiomyopathy

​Affinia Therapeutics has received approval from the US FDA for an IND application to initiate the UPBEAT Phase I/II trial of AFTX-201, an investigational gene therapy for adults with BAG3-related DCM.

The post Affinia receives FDA approval for Phase I/II trial for dilated cardiomyopathy appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.